Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

21. eHealth interventions for people with chronic kidney disease. Full Text available with Trip Pro

eHealth interventions for people with chronic kidney disease. Chronic kidney disease (CKD) is associated with high morbidity and death, which increases as CKD progresses to end-stage kidney disease (ESKD). There has been increasing interest in developing innovative, effective and cost-efficient methods to engage with patient populations and improve health behaviours and outcomes. Worldwide there has been a tremendous increase in the use of technologies, with increasing interest in using eHealth (...) interventions to improve patient access to relevant health information, enhance the quality of healthcare and encourage the adoption of healthy behaviours.This review aims to evaluate the benefits and harms of using eHealth interventions to change health behaviours in people with CKD.We searched the Cochrane Kidney and Transplant Register of Studies up to 14 January 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through

2019 Cochrane

22. Chronic renal diseases and pregnancy

.” International Journal of Women’s Health 8 (July): 273–85. Gonzalez Suarez, Maria L., Andrea Kattah, Joseph P. Grande, and Vesna Garovic. 2018. “Renal Disorders in Pregnancy: Core Curriculum 2019.” American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, August. https://doi.org/10.1053/j.ajkd.2018.06.006. Hladunewich, Michelle A. 2017. “Chronic Kidney Disease and Pregnancy.” Seminars in Nephrology 37 (4): 337–46. Imbasciati, Enrico, Gina Gregorini, Gianfranca Cabiddu (...) in English (4 pages) 2. Entire guideline in Danish (35 pages) Summary of clinical recommendations: Chronic Kidney Disease and pregnancy: CKD Recommendations Level of evidence Recommendation Preconception Counselling in cooperation with a nephrologist and an obstetrician with special interest in nephrology A Level of renal impairment, presence of hypertension and proteinuria are the strongest prognostics for the outcome of the pregnancy as well as the risk of progression of renal disease /progression

2019 Nordic Federation of Societies of Obstetrics and Gynecology

23. Tolvaptan (Jinarc ) for the treatment of chronic kidney disease - alteration of the specific conditions

Tolvaptan (Jinarc ) for the treatment of chronic kidney disease - alteration of the specific conditions Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions | Report | National Health Care Institute You are here: Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions Search within English part of National Health Care Institute Search Tolvaptan (Jinarc ®) for the treatment of chronic kidney (...) supportive care for ADPKD patients with chronic kidney disease (CKD) stages 1 to 3. For the effectiveness of tolvaptan in patients with CKD stage 3b, the evidence was scant. As a result, reimbursement is currently possible based on the following condition: Only for an insured person aged 18 years and older with autosomal dominant polycystic kidney disease (ADPKD) with chronic kidney disease (CKD) in stages 1 to 3a at the start of the treatment, with evidence of rapidly progressing disease, and in line

2019 National Health Care Institute (Zorginstituut Nederland)

24. Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. (Abstract)

Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. Intradialytic hypotension (IDH) is a common complication of haemodialysis (HD), and a risk factor of cardiovascular morbidity and death. Several clinical studies suggested that reduction of dialysate temperature, such as fixed reduction of dialysate temperature or isothermal dialysate using a biofeedback system, might improve the IDH rate.This review aimed to evaluate (...) the benefits and harms of dialysate temperature reduction for IDH among patients with chronic kidney disease requiring HD, compared with standard dialysate temperature.We searched Cochrane Kidney and Transplant's Specialised Register up to 14 May 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search

2019 Cochrane

25. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. (Abstract)

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. Metabolic acidosis, a complication of chronic kidney disease, causes protein catabolism and bone demineralisation and is associated with adverse kidney outcomes and mortality. Veverimer, a non-absorbed, counterion-free, polymeric drug candidate selectively binds and removes hydrochloric acid from the gastrointestinal (...) lumen.We did a multicentre, randomised, blinded, placebo-controlled, 40-week extension of a 12-week parent study at 29 sites (hospitals and specialty clinics) in seven countries (Bulgaria, Georgia, Hungary, Serbia, Slovenia, Ukraine, and the USA). Eligible patients were those with chronic kidney disease (estimated glomerular filtration rate 20-40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate 12-20 mmol/L), who had completed the 12-week parent study, for which they were randomly assigned

2019 Lancet Controlled trial quality: predicted high

26. Use of Peripherally Inserted Central Catheters in Patients With Advanced Chronic Kidney Disease: A Prospective Cohort Study. (Abstract)

Use of Peripherally Inserted Central Catheters in Patients With Advanced Chronic Kidney Disease: A Prospective Cohort Study. Existing guidelines, including Choosing Wisely recommendations, endorse avoiding placement of peripherally inserted central catheters (PICCs) in patients with chronic kidney disease (CKD).To describe the frequency of and characteristics associated with PICC use in hospitalized patients with stage 3b or greater CKD (glomerular filtration rate [GFR] <45 mL/min/1.73 m2

2019 Annals of Internal Medicine

27. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, plac Full Text available with Trip Pro

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, plac In patients with type 2 diabetes, intensive glucose control can be renoprotective and albuminuria-lowering treatments can slow the deterioration of kidney function. We assessed the albuminuria-lowering effect of the sodium-glucose co (...) groups. There were no new drug-related safety signals.Dapagliflozin with or without saxagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment, is a potentially attractive option to slow the progression of kidney disease in patients with type 2 diabetes and moderate-to-severe chronic kidney disease.AstraZeneca.Copyright © 2019 Elsevier Ltd. All rights reserved.

2019 EvidenceUpdates

28. Undernutrition in Chronic Kidney Disease

energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism. Journal of Renal Nutrition 2013; 23: 77-90. 24. Koo JR, Park KY, Kim HJ, Che DW, Lee JS, Son BW, Rho JW. Depression in chronic haemodialysis patients: risk factors and effects on nutritional parameters. Journal of the American Society of Nephrology 1998; 9: 216A 25. Kopple JD, Greene T, Chumlea WC, Hollinger D, Maroni BJ, Merrill D, Scherch LK, Schulman G, Wang SR (...) Undernutrition in Chronic Kidney Disease Clinical Practice Guideline Undernutrition in Chronic Kidney Disease Authors: Dr Mark Wright Consultant Nephrologist, St J am es ’s University Hospital, Leeds Mrs Elizabeth Southcott Senior Specialist Renal Dietitian, St J a m es’s University Hospital, Leeds Dr Helen MacLaughlin, Consultant Dietitian, Kings College Hospital Mr Stuart Wineberg Patient Representative Final Version: June 2019 Review Date: June 2024 2 Endorsements The National Institute

2019 Renal Association

29. Growth Monitoring for Children with Chronic Kidney Disease

). However the frequency of measurement we recommend provides significant benefits in our opinion but has a weak evidence base due to a general lack of studies in this area(1D). This guideline is endorsed by The British Society for Paediatric Endocrinology and Diabetes (BSPED), The British Association for Paediatric Nephrology (BAPN) and The Paediatric Renal Interest Nutrition Group (PRING). Stages of Chronic Kidney Disease (CKD) 14 Stage GFR* Description Management 1 > 90 Normal Renal Function (...) and anthropometric and nutritional measurements in children with mild to moderate renal insufficiency: a report of the Growth Failure in Children with Renal Diseases study. J Paediatr. 1990; 116: S46 – 54 2. Norman LJ, Coleman JE, MacDonald 1A, Thomsett AM, Watson AR: Nutrition and Growth in relation to severity of renal disease in children, Paediatric Nephrology 2000; 15, 259-65. 3. Kari JA, Gonzalez C, Lederman S, Shaw V, Rees L: Outcome and Growth of Infants with Severe Chronic Renal Failure. Kidney

2019 British Society for Paediatric Endocrinology and Diabetes

30. Interventions for improving sleep quality in people with chronic kidney disease. (Abstract)

Interventions for improving sleep quality in people with chronic kidney disease. Sleep disorders are commonly experienced by people with chronic kidney disease (CKD). Several approaches for improving sleep quality are used in clinical practice including relaxation techniques, exercise, acupressure, and medication.To assess the effectiveness and associated adverse events of interventions designed to improve sleep quality among adults and children with CKD including people with end-stage kidney (...) disease (ESKD) treated with dialysis or kidney transplantation.We searched the Cochrane Kidney and Transplant Register of Studies up to 8 October 2018 with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We included randomised controlled trials (RCTs) or quasi-randomised RCTs

2019 Cochrane

31. Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study. Full Text available with Trip Pro

Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study. To investigate the relation between preterm birth (gestational age <37 weeks) and risk of CKD from childhood into mid-adulthood.National cohort study.Sweden.4 186 615 singleton live births in Sweden during 1973-2014.Gestational age at birth, identified from nationwide birth records in the Swedish birth registry.CKD, identified from nationwide inpatient and outpatient diagnoses through 2015 (...) males and females and did not seem to be related to shared genetic or environmental factors in families.Preterm and early term birth are strong risk factors for the development of CKD from childhood into mid-adulthood. People born prematurely need long term follow-up for monitoring and preventive actions to preserve renal function across the life course.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com

2019 BMJ

32. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. (Abstract)

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes.We did this double-blind, randomised, placebo-controlled trial (...) occurred in 47 (3·5%) of 1325 patients in the atrasentan group and 34 (2·6%) of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85-2·07]; p=0·208). 58 (4·4%) patients in the atrasentan group and 52 (3·9%) in the placebo group died (HR 1·09 [95% CI 0·75-1·59]; p=0·65).Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists

2019 Lancet Controlled trial quality: predicted high

33. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. (Abstract)

Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Patients with advanced chronic kidney disease lose the capacity to fully excrete endogenous acid, resulting in chronic metabolic acidosis that increases the risk of disease progression and causes muscle catabolism and bone resorption. Veverimer, a non-absorbed, counterion-free, polymeric drug, selectively binds and removes (...) participants were patients aged 18-85 years with non-dialysis-dependent chronic kidney disease (estimated glomerular filtration rate of 20-40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate concentration of 12-20 mmol/L). Patients were randomly assigned (4:3) to veverimer 6 g/day or placebo for 12 weeks while they consumed their typical diet. Both drugs were taken as oral suspensions in water with lunch. Randomisation was done by study site personnel with a computer-generated randomisation

2019 Lancet Controlled trial quality: predicted high

34. Patiromer (Veltassa) - for the treatment of hyperkalemia in adults with chronic kidney disease

Patiromer (Veltassa) - for the treatment of hyperkalemia in adults with chronic kidney disease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs

2019 Health Canada - Drug and Health Product Register

35. Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronic kidney disease or primary hypertension

). The remaining studies considered different populations. One study included people with chronic renal insufficiency (mild to severe CKD), one study assessed people with CKD and kidney transplant patients, and one study included only people with IgA nephropathy. Four studies assessed ACR and PCR by using both tests to predict proteinuria at baseline, and then comparing these findings with long-term clinical outcomes. Outcomes measured varied between studies, but included all-cause mortality and kidney disease (...) Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronic kidney disease or primary hypertension Page 1 of 6 TER005 December 2018 Topic Exploration Report Topic explorations are designed to provide a high-level briefing on new topics submitted for consideration by Health Technology Wales. The main objectives of this report are to: 1. Inform discussions on new topics received by HTW. 2. Determine the quantity and type of evidence available

2019 Health Technology Wales

36. General medicine: Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation

General medicine: Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation Article Text Commentary General medicine Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation David Massicotte-Azarniouch 1 , Manish M Sood 1 , 2

2019 Evidence-Based Medicine

37. Chronic kidney disease

disease. Early identification and management of chronic kidney disease in adults in primary and secondary care [ ]. This CKS topic covers the identification and management of chronic kidney disease in adults. This CKS topic does not cover the diagnosis or management of acute kidney injury (AKI), or the detailed management of complications of chronic kidney disease, such as renal anaemia and mineral and bone disorder. There are separate CKS topics on , , , , and . The target audience for this CKS topic (...) . Cardiovascular disease. See the CKS topics on , , , , and for more information. Obesity with metabolic syndrome. Obesity alone is not a risk factor for CKD. See the CKS topics on and for more information. [ ; ; ; ; ; ] Prevalence How common is it? The incidence and prevalence of chronic kidney disease (CKD) varies depending on the population studied, including ethnic group and socio-economic class [ ; ] . The large UK 'New Opportunities for Early Renal Intervention by Computerised Assessment' (NEOERICA

2019 NICE Clinical Knowledge Summaries

38. Chronic Kidney Disease - Identification, Evaluation and Management of Adult Patients

renal disease (ESRD), often requiring dialysis or kidney transplantation , , . Most patients with chronic kidney disease die from other comorbidities before they progress to kidney failure. The outcome of many patients who go on to dialysis remains poor with 10 percent annual mortality; the overall 5 year survival rate is worse than that of most cancers . Evidence clearly indicates that control of hypertension and proteinuria can prevent or postpone kidney function decline . This underscores (...) and they often co-exist . Even if the cause seems obvious (e.g., diabetes), the possibility of a serious underlying primary renal disorder (e.g. glomerulonephritis) must be considered in patients with: Abnormal urinalysis, (e.g. proteinuria, hematuria, cellular casts). Note: hyaline casts are normal . Rapid sustained decline in kidney function (change in eGFR > 10-15%/year) despite remedy of reversible precipitants (e.g. volume contraction, febrile illness, medications). Constitutional symptoms suggesting

2019 Clinical Practice Guidelines and Protocols in British Columbia

39. General medicine: Heat-related chronic kidney disease mortality in the young and old: differing mechanisms, potentially similar solutions?

activity mediates dehydration-induced renal injury . 15. Brooks DR , Ramirez-Rubio O , Amador JJ . CKD in Central America: a hot issue . 16. Jayasumana C , Gunatilake S , Senanayake P . Glyphosate, hard water and nephrotoxic metals: are they the culprits behind the epidemic of chronic kidney disease of unknown etiology in Sri Lanka? 17. Rampazzo N , Rampazzo Todorovic G , Mentler A , et al . Adsorption of glyphosate and aminomethylphosphonic acid in soils . 18. Ayoola S . Histopathological effects (...) General medicine: Heat-related chronic kidney disease mortality in the young and old: differing mechanisms, potentially similar solutions? Heat-related chronic kidney disease mortality in the young and old: differing mechanisms, potentially similar solutions? | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu

2019 Evidence-Based Medicine

40. Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery Full Text available with Trip Pro

Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery No medical intervention has been identified that decreases acute kidney injury and improves renal outcome at 1 year after cardiac surgery.To determine whether administration of nitric oxide reduces the incidence of postoperative acute kidney injury and improves long-term kidney outcomes after multiple cardiac valve replacement requiring prolonged cardiopulmonary bypass.Two hundred and forty-four (...) group) to 50% (nitric oxide group) (relative risk [RR], 0.78; 95% confidence interval [CI], 0.62-0.97; P = 0.014). Secondary outcomes were as follows: at 90 days, transition to stage 3 chronic kidney disease was reduced from 33% in the control group to 21% in the treatment group (RR, 0.64; 95% CI, 0.41-0.99; P = 0.024) and at 1 year, from 31% to 18% (RR, 0.59; 95% CI, 0.36-0.96; P = 0.017). Nitric oxide treatment reduced the overall major adverse kidney events at 30 days (RR, 0.40; 95% CI, 0.18-0.92

2018 EvidenceUpdates